Supriya Lifescience Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Supriya Lifescience Ltd filed with BSE on 02 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Supriya Lifescience reported record quarterly revenue of INR277 crores in Q4 FY26, up 50% year-on-year, with full-year FY26 revenue of INR828 crores, up 18.9%, and EBITDA margin of 35.5%. Management said the Lote facility received a USFDA Establishment Inspection Report with Voluntary Action Indicated classification after a surprise inspection with only one minor observation. Management also discussed new product launches including a cardiovascular intermediate and an ADHD product, and reiterated a target of INR1,000 crores revenue by FY27.
Numbers mentioned
Revenue: INR277 crores (Q4 FY26)
p. 4
“a record quarterly revenue achieved in Q4 FY26 of INR277 crores”
Satish Wagh, page 4 of the filed PDF · View the filing
Revenue growth: 18.9% year-on-year (FY26)
p. 4
“Financial year '26 revenue grew to 18.9% year-on-year to INR828 crores”
Satish Wagh, page 4 of the filed PDF · View the filing
EBITDA margin: 35.5% (FY26)
p. 4
“while EBITDA stood at INR294 crores with a robust margin of 35.5%”
Satish Wagh, page 4 of the filed PDF · View the filing
Export segment share of revenue: 82% (FY26)
p. 4
“Export segment, a key growth driver contributing 82% of the financial year revenues.”
Satish Wagh, page 4 of the filed PDF · View the filing
Europe share of revenue: 40% (FY26)
p. 4
“Europe delivered healthy growth with a 40% share during the year.”
Satish Wagh, page 4 of the filed PDF · View the filing
Backward integration: 76% (FY26)
p. 4
“Backward integration initiatives, which also progressed in financial year '26 at 76%, strengthening cost efficiency and supporting sustainable growth.”
Satish Wagh, page 4 of the filed PDF · View the filing
Revenue: INR184 crores (Q4 FY25)
p. 5
“the company reported revenue from operations of INR277 crores as against INR184 crores in Q4 FY25, a growth of 50% year-on-year”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
EBITDA: INR98 crores (Q4 FY26)
p. 5
“EBITDA for the quarter stood at INR98 crores as against INR68 crores in Q4 FY25, a growth of 44% year-on-year”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
PAT: INR74 crores (Q4 FY26)
p. 5
“PAT stood at INR74 crores as against INR50 crores in Q4 FY25.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
PAT margin: 26.8% (Q4 FY26)
p. 5
“PAT margin stood at 26.8% for Q4 FY26.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
EBITDA: INR294 crores (FY26)
p. 5
“EBITDA stood at INR294 crores as against INR261 crores in FY25, a growth of 13% year-on-year.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
PAT: INR209 crores (FY26)
p. 5
“PAT stood at INR209 crores.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
PAT margin: 25.3% (FY26)
p. 5
“PAT margins were at 25.3% for FY26.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
Capex: INR152 crores (FY26)
p. 5
“Our capex for FY26 at INR152 crores, largely driven by spend on Ambernath facility along with maintenance capex and smaller projects, including the Ribo Block and formulation plant requirements.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
Patalganga Phase 1 capex: around INR200 crores
p. 5
“The total capex earmarked for this facility is around INR200 crores for Phase 1.”
Krishna Raghunathan, page 5 of the filed PDF · View the filing
Q4 FY26 revenue impact from headwinds: INR10 crores (Q4 FY26)
p. 4
“which impacted our Q4 FY26 revenue by INR10 crores”
Satish Wagh, page 4 of the filed PDF · View the filing
DSM revenue: INR30 crores to INR35 crores (FY26)
p. 9
“So DSM actually has contributed to the tune of INR30 crores, INR35 crores in the last financial year.”
Saloni Wagh, page 9 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — approximately 20% annual growth · FY27
stated firmly by Satish Wagh
p. 4
“We iterate our guidance of approximately 20% annual growth revenue and EBITDA margin, 33% to 35%.”
Satish Wagh, page 4 of the filed PDF · View the filing
Revenue milestone — INR1,000 crores · FY27
stated firmly by Satish Wagh
p. 4
“Our trajectory towards the INR1,000 crores revenue milestone by financial year '27 remains firmly on track, underpinned by a robust pipeline.”
Satish Wagh, page 4 of the filed PDF · View the filing
EBITDA margin — 33% to 35%
stated firmly by Saloni Wagh
p. 14
“The EBITDA margin, 33% to 35% is something that we would like to continue guiding”
Saloni Wagh, page 14 of the filed PDF · View the filing
Contrast media product launch — H2 FY27
stated conditionally by Satish Wagh
p. 4
“It is expected to be launching H2 financial year '27.”
Satish Wagh, page 4 of the filed PDF · View the filing
New product launches in anesthetics and ADHD — ~2 new launches in each segment · FY27
stated as an aspiration by Satish Wagh
p. 4
“For financial year '27, we plan to further strengthen our anesthetics and ADHD portfolios with ~2 new launch in each segment aimed at enhancing pipeline depth and supporting broader market penetration, along with the sustained growth.”
Satish Wagh, page 4 of the filed PDF · View the filing
Patalganga Phase 1 groundbreaking — FY27
stated firmly by Satish Wagh
p. 4
“We are also glad to share that we have secured all clearances for the Patalganga land, with phased development to begin with Phase 1 groundbreaking in financial year '27.”
Satish Wagh, page 4 of the filed PDF · View the filing
F block capacity addition — 150 to 200 KL · next 2 years
stated firmly by Saloni Wagh
p. 9
“So we are planning to add about 150 to 200 KL further the capacity and this will come up in the next 2 years' time.”
Saloni Wagh, page 9 of the filed PDF · View the filing
F block capex — INR40 crores to INR50 crores
stated firmly by Saloni Wagh
p. 9
“We are expecting about INR40 crores to INR50 crores of capex dedicated for the F block.”
Saloni Wagh, page 9 of the filed PDF · View the filing
DSM revenue peak — INR60 crores · FY27
stated as an aspiration by Saloni Wagh
p. 9
“And the peak that we expect is about INR60 crores, which we'll be able to see in FY27.”
Saloni Wagh, page 9 of the filed PDF · View the filing
EU-GMP audit for Ambernath — H2 FY27
stated conditionally by Saloni Wagh
p. 12
“the EU audit is scheduled for H2 FY27, but we still have not got the dates for USFDA audit”
Saloni Wagh, page 12 of the filed PDF · View the filing
GLP-1 product revenue — at least 2 years
stated conditionally by Saloni Wagh
p. 15
“So, revenue will take at least 2 years because the development has also not started.”
Saloni Wagh, page 15 of the filed PDF · View the filing
Net working capital days — 170 to 180 days · FY27
stated firmly by Krishna Raghunathan
p. 15
“We are looking at around 170 to 180 days going forward.”
Krishna Raghunathan, page 15 of the filed PDF · View the filing
Receivable days — 80 to 85 days
stated firmly by Krishna Raghunathan
p. 16
“See, we will be able to maintain between 80 to 85 days even at the worst of times.”
Krishna Raghunathan, page 16 of the filed PDF · View the filing
Effective tax rate — 25.17% · FY27
stated firmly by Krishna Raghunathan
p. 11
“So, for full year, you can expect somewhere around say 25.17%.”
Krishna Raghunathan, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the anesthetic portfolio, cardiovascular, vitamins and anti-hypertensive products all contributed and growth is broad-based, not one-time.
Answered by Saloni Wagh
Asked by Rachna Kukreja: What other therapeutic areas drove the ~9% non-top-category revenue contribution in FY26 and is it one-time?
p. 6
“Having said that, other than anesthesia, antihistamines are fairly stable. Vitamins, we have actually seen a very good growth because also the DSM volumes have now stabilized.”
Saloni Wagh, page 6 of the filed PDF · View the filing
Management said the product is scaling well and the 300 metric ton figure will be approached in FY27 based on current order book, with contracts locked in with three to four large users.
Answered by Saloni Wagh
Asked by Sanjay Kumar: Has the 300-ton cardiovascular intermediate order been converted to a final order and can it be fully utilized in FY27?
p. 8
“So we have seen very good scale-up of this advanced intermediate in quarter 4. Already, we have started seeing revenue contribution and the 300 metric ton, I think will come very close to that number in FY27, looking at the current order book that we have.”
Saloni Wagh, page 8 of the filed PDF · View the filing
Management said the company has not enrolled in any PLI scheme and does not intend to, focusing instead on customer qualification.
Answered by Saloni Wagh
Asked by Sanjay Kumar: Is Supriya enrolled in the PLI scheme for the cardiovascular intermediate?
p. 8
“From the regulatory perspective, we have not enrolled ourselves into any PLI scheme.”
Saloni Wagh, page 8 of the filed PDF · View the filing
Management said quarter-on-quarter guidance isn't given and growth will not be linear due to a planned shutdown, but the INR1,000 crores FY27 target remains.
Answered by Saloni Wagh
Asked by Darshil Jhaveri: Can the Q4 FY26 revenue run rate of INR270 crores be maintained going forward?
p. 11
“So no, I mean we'll not be able to give any quarter-on-quarter guidance of the run rate.”
Saloni Wagh, page 11 of the filed PDF · View the filing
Management declined to comment on gross margin specifically but explained EBITDA margin appeared lower due to Ambernath expenses starting before its revenue.
Answered by Saloni Wagh
Asked by Aditya: What caused the dip in gross margin this quarter?
p. 12
“So that is one of the reasons why although the EBITDA has grown in absolute terms in terms of percentage, it looks slightly lower than the last financial year only because the expense part of Ambernath has now started.”
Saloni Wagh, page 12 of the filed PDF · View the filing
Management said discussions are at an advanced stage but no agreement has been signed.
Answered by Saloni Wagh
Asked by Deepankar Bisht: Is the GLP-1 product development with an Indian generic company a signed agreement?
p. 14
“It's still in discussion phase, but it is at a very advanced discussion phase, but we still have not signed the agreement.”
Saloni Wagh, page 14 of the filed PDF · View the filing
Management attributed higher inventory to backward integration requiring larger intermediate stock and to Ambernath inventory build-up.
Answered by Krishna Raghunathan
Asked by Sajal Kapoor: Is the elevated inventory days a deliberate buffer or a near-term blip?
p. 15
“And specifically, like the cardiovascular product as well as the liquid anesthetic, I think since the capacities are huge, even the intermediates, what we had to hold are becoming huge.”
Krishna Raghunathan, page 15 of the filed PDF · View the filing
Management said the company has now achieved full backward integration for the product after volumes scaled up.
Answered by Saloni Wagh
Asked by Sanjay Kumar: What is the backward integration status for the cardiovascular product's process steps?
p. 17
“So, at this point, we have already gone to full backward integration because when the volumes scaled up, we were waiting for the volumes to scale up, now that the volumes have scaled up, we have already fully backward integrated.”
Saloni Wagh, page 17 of the filed PDF · View the filing
Risks flagged
Geopolitical and supply chain headwinds including elevated crude and solvent prices and intermittent shortages impacted quarterly revenue
p. 4
“During Q4, industry-wide headwinds arose from geopolitical challenges, including supply chain disruptions, elevated crude and solvent prices and intermittent shortages, which impacted our Q4 FY26 revenue by INR10 crores.”
Satish Wagh, page 4 of the filed PDF · View the filing
Planned annual maintenance shutdown will disrupt linear quarterly growth
p. 4
“However, the growth won't be linear across the quarter as we have scheduled our annual maintenance shutdown in August for our older blocks A&D.”
Satish Wagh, page 4 of the filed PDF · View the filing
Ambernath facility expenses have started while revenue contribution has not yet begun, pressuring margin optics
p. 12
“So that is one of the reasons why although the EBITDA has grown in absolute terms in terms of percentage, it looks slightly lower than the last financial year only because the expense part of Ambernath has now started.”
Saloni Wagh, page 12 of the filed PDF · View the filing
Delay in obtaining USFDA audit dates for Ambernath due to auditor unavailability
p. 12
“However, due to unavailability of auditors, we are not able to get a data as of now.”
Saloni Wagh, page 12 of the filed PDF · View the filing
Delay in European auditor visit for the formulation facility
p. 10
“So no, we have not been able to get the audit dates from the auditors.”
Saloni Wagh, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.